[Membrane defect as a basic disorder of the growth control mechanism in psoriasis pathogenetic concept and therapeutic consequences (author's transl)].
The system glycocalyz - membrane bound enzymes - cAMP may be regarded as a regulatory mechanism for the control of epidermal growth. The glycocalyz of the epithelial cell membrane is obviously a receptor and accumulator for agents stimulating adenyl cyclase and other membrane-bound enzymes of energy utilisation; cAMP, on the other hand, serves as an intracellular 'mediator' between proliferative stimuli and the DNA of the keratinocytes. Numerous cytological, cytochemical, and enzymatic biochemical studies indicate that this mechanism is profoundly disturbed in psoriasis, particularly at the membrane-bound stage.
D000262:Adenylyl Cyclases / Q000378:metabolism; D002455:Cell Division; D002462:Cell Membrane / Q000201:enzymology* / Q000276:immunology / Q000378:metabolism; D002463:Cell Membrane Permeability; D000242:Cyclic AMP / Q000378:metabolism; D006023:Glycoproteins / Q000378:metabolism; D006131:Growth Inhibitors / Q000378:metabolism; D006680:HLA Antigens; D006801:Humans; D011134:Polysaccharides / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy / Q000201:enzymology*; D012867:Skin / Q000201:enzymology* / Q000378:metabolism; D013431:Sulfates / Q000627:therapeutic use
D006023:Glycoproteins; D006131:Growth Inhibitors; D006680:HLA Antigens; D011134:Polysaccharides; D013431:Sulfates; D000242:Cyclic AMP; D000262:Adenylyl Cyclases
Membrandefekt als Basis der gestörten Wachstumsregulation bei Psoriasis. Pathogenetisches Konzept und Therapeutische Konsequenzen